|
Lanreotide for the prolonged control of carcinoid syndrome (CS) in somatostatin analog (SSA)-naïve or experienced patients. |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Lexicon; Novartis |
|
|
Stock and Other Ownership Interests - Seagen (I) |
Honoraria - Merck, Genentech, Ipsen |
Consulting or Advisory Role - Celgene; ipsen |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); EpicentRx (Inst); Forty seven (Inst); Genentech/Roche (Inst); Ipsen (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmaceutical Research Associates (Inst); Polaris (Inst); Sun Pharma (Inst); XBiotech (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Merck |
|
|
|
Stock and Other Ownership Interests - Ipsen |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Ipsen |
|
|
|
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Alnylam; Astellas Pharma; Ipsen; Janssen; Merck; Pamlab; VeroScience |
Speakers' Bureau - Lexicon; Merck |
Research Funding - Impeto Medical (Inst); Novo Nordisk (Inst); VeroScience (Inst); ViroMed (Inst) |
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pamlab; Pfizer; Regeneron; VeroScience |